Repligen Appoints Jacob Johnson As Vice President Investor Relations
Repligen (NASDAQ:RGEN) has appointed Jacob Johnson as Vice President of Investor Relations. Johnson, who previously served as Managing Director and Research Analyst at Stephens Inc., will lead investor relations and report to CFO Jason K. Garland.
Johnson brings significant experience in the life sciences tools and pharma services sector, having covered Repligen as a research analyst since 2019. He previously worked as a research associate on Stephens' healthcare services team and in investment management. Johnson holds a B.A. in Economics and Mathematics from Sewanee and an M.S. Finance from Washington University's Olin Business School.
He succeeds Sondra Newman, who is retiring after leading global investor relations and corporate communications since 2012.
Repligen (NASDAQ:RGEN) ha nominato Jacob Johnson come Vice Presidente delle Relazioni con gli Investitori. Johnson, che in precedenza ha ricoperto il ruolo di Direttore Generale e Analista di Ricerca presso Stephens Inc., guiderà le relazioni con gli investitori e riporterà al CFO Jason K. Garland.
Johnson porta con sé una significativa esperienza nel settore degli strumenti per le scienze della vita e dei servizi farmaceutici, avendo seguito Repligen come analista di ricerca dal 2019. Ha lavorato in precedenza come associato di ricerca nel team di servizi sanitari di Stephens e nella gestione degli investimenti. Johnson ha conseguito una laurea in Economia e Matematica presso Sewanee e un M.S. in Finanza presso la Olin Business School dell'Università di Washington.
Succede a Sondra Newman, che si ritira dopo aver guidato le relazioni globali con gli investitori e le comunicazioni aziendali dal 2012.
Repligen (NASDAQ:RGEN) ha nombrado a Jacob Johnson como Vicepresidente de Relaciones con Inversores. Johnson, quien anteriormente se desempeñó como Director General y Analista de Investigación en Stephens Inc., liderará las relaciones con los inversores y reportará al CFO Jason K. Garland.
Johnson aporta una experiencia significativa en el sector de herramientas para ciencias de la vida y servicios farmacéuticos, habiendo cubierto a Repligen como analista de investigación desde 2019. Anteriormente trabajó como asociado de investigación en el equipo de servicios de salud de Stephens y en gestión de inversiones. Johnson tiene una licenciatura en Economía y Matemáticas de Sewanee y una Maestría en Finanzas de la Escuela de Negocios Olin de la Universidad de Washington.
Sucede a Sondra Newman, quien se retira después de liderar las relaciones globales con inversores y comunicaciones corporativas desde 2012.
Repligen (NASDAQ:RGEN)은 Jacob Johnson을 투자자 관계 부사장으로 임명했습니다. Johnson은 이전에 Stephens Inc.에서 전무이사 및 연구 분석가로 일했으며, 투자자 관계를 이끌고 CFO Jason K. Garland에게 보고할 것입니다.
Johnson은 2019년부터 연구 분석가로서 Repligen을 다루며 생명 과학 도구 및 제약 서비스 분야에서 상당한 경험을 쌓았습니다. 그는 이전에 Stephens의 의료 서비스 팀에서 연구 보조원으로 일했으며, 투자 관리 분야에서도 활동했습니다. Johnson은 Sewanee에서 경제학 및 수학 학사 학위를, 워싱턴 대학교 Olin 경영대학원에서 금융 석사 학위를 취득했습니다.
그는 2012년부터 글로벌 투자자 관계 및 기업 커뮤니케이션을 이끌어온 Sondra Newman의 뒤를 이어 취임합니다.
Repligen (NASDAQ:RGEN) a nommé Jacob Johnson au poste de Vice-Président des Relations Investisseurs. Johnson, qui a précédemment été Directeur Général et Analyste de Recherche chez Stephens Inc., dirigera les relations avec les investisseurs et rendra compte au CFO Jason K. Garland.
Johnson apporte une expérience significative dans le secteur des outils pour les sciences de la vie et des services pharmaceutiques, ayant suivi Repligen en tant qu'analyste de recherche depuis 2019. Il a précédemment travaillé comme associé de recherche dans l'équipe des services de santé de Stephens et dans la gestion d'investissements. Johnson est titulaire d'un B.A. en Économie et Mathématiques de Sewanee et d'un M.S. en Finance de l'Olin Business School de l'Université de Washington.
Il succède à Sondra Newman, qui prend sa retraite après avoir dirigé les relations investisseurs mondiales et les communications d'entreprise depuis 2012.
Repligen (NASDAQ:RGEN) hat Jacob Johnson zum Vizepräsidenten für Investor Relations ernannt. Johnson, der zuvor als Geschäftsführer und Research Analyst bei Stephens Inc. tätig war, wird die Investor Relations leiten und an CFO Jason K. Garland berichten.
Johnson bringt umfangreiche Erfahrung im Bereich der Lebenswissenschaften und pharmazeutischen Dienstleistungen mit, da er Repligen seit 2019 als Research Analyst betreut hat. Zuvor arbeitete er als Research Associate im Healthcare-Service-Team von Stephens und im Investment Management. Johnson hat einen B.A. in Wirtschaft und Mathematik von Sewanee und einen M.S. in Finanzen von der Olin Business School der Washington University.
Er folgt auf Sondra Newman, die nach ihrer Leitung der globalen Investor Relations und Unternehmenskommunikation seit 2012 in den Ruhestand geht.
- New VP IR brings deep industry knowledge having covered Repligen since 2019
- Smooth transition expected due to Johnson's familiarity with company and technologies
- Strong educational and professional background in finance and healthcare sector analysis
- Loss of long-term IR leadership with Newman's retirement after 11 years
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector.
Mr. Garland commented, “Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth drivers for our industry and the company. Jacob has covered Repligen as a research analyst since 2019; his immediate familiarity with the company and our technologies will enable Jacob to seamlessly engage with the investor audience and pick up leadership of the IR function.”
Mr. Garland added, “While welcoming Jacob, we sincerely wish Sondra Newman happiness and success in her next endeavors as she retires from Repligen following a transition period. As our outgoing Vice President Investor Relations, Sondra has done a remarkable job leading global investor relations and corporate communications for the Company since 2012 and will truly be missed.”
Prior to his most recent role at Stephens, Mr. Johnson worked as a research associate on the firm’s healthcare services team. Before joining Stephens in 2015, he worked in the investment management industry. Mr. Johnson holds a B.A. in Economics and Mathematics from Sewanee: The University of the South and a M.S. Finance from the Olin Business School at Washington University in St. Louis.
About Repligen
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
Repligen Contact:
Jason K. Garland
Chief Financial Officer
(781)250-0111
investors@repligen.com
FAQ
Who is the new Vice President of Investor Relations at Repligen (RGEN)?
What is Jacob Johnson's background before joining Repligen (RGEN)?
Who did Jacob Johnson replace at Repligen (RGEN)?
What are Jacob Johnson's qualifications for the RGEN IR position?
